Pharsight

Vagifem generic

Vagifem is a drug owned by Novo Nordisk Inc. The active ingredient is estradiol, which forms the basis of its therapeutic uses. Vagifem received market authorization on 26th March 1999. In total, it has 1 drug patent, with all now being expired.

When will Vagifem generic be available?

The generics of Vagifem became possible to be released after 17th September, 2022 following the expiration of the last patent (US7018992). This remains the pivotal date for the inception of Vagifem generic variants.

Vagifem uses

Vagifem is primarily deployed in the treatment of atrophic vaginitis, a condition usually prompted by menopause. The effectiveness of the drug can be attributed to the presence of estradiol, an estrogen hormone which helps maintain and repair the vaginal tissues.

Vagifem patent expiration

Vagifem had a total of 1 drug patent named US7018992, the details for the patent are as follow: Patent US7018992 with the title 'Hormone Composition', which expired on 17th September, 2022. This event led to the possibility of the emergence of Vagifem generic alternatives. Below are the details of the patent:

EPO Oppostions filed on Vagifem

Vagifem dosage

Want to ask something?